TY - JOUR
T1 - Alprazolam and DN-2327 (Pazinaclone) in Humans
T2 - Psychomotor, Memory, Subjective, and Reinforcing Effects
AU - Mumford, Geoffrey K.
AU - Rush, Craig R.
AU - Griffiths, Roland R.
PY - 1995/2
Y1 - 1995/2
N2 - The psychomotor, memory, subjective, and reinforcing effects of DN-2327 (DN), a novel partial agonist at benzodiazepine receptors, were compared with those of alprazolam (AL) in 14 men with histories of sedative drug abuse. Placebo, DN (8, 16, and 32 mg), and AL (0.5, 1.0, and 2.0 mg) were administered orally in a randomized, double-blind, cross-over design. DN and AL produced similar maximal impairment on psychomotor and memory performance. AL produced greater increases in participant ratings of sedation and a variety of somatic symptoms that were absent following DN. Abuse liability measures showed both drugs increased liking and good effects and were categorized by participants as sedative-hypnotics; however, 2 of 3 indirect and 1 direct measure of drug reinforcement were greater with AL than with DN. The dissociation between psychomotor-memory performance effects and various subjective effects demonstrates a novel pharmacological profile of DN.
AB - The psychomotor, memory, subjective, and reinforcing effects of DN-2327 (DN), a novel partial agonist at benzodiazepine receptors, were compared with those of alprazolam (AL) in 14 men with histories of sedative drug abuse. Placebo, DN (8, 16, and 32 mg), and AL (0.5, 1.0, and 2.0 mg) were administered orally in a randomized, double-blind, cross-over design. DN and AL produced similar maximal impairment on psychomotor and memory performance. AL produced greater increases in participant ratings of sedation and a variety of somatic symptoms that were absent following DN. Abuse liability measures showed both drugs increased liking and good effects and were categorized by participants as sedative-hypnotics; however, 2 of 3 indirect and 1 direct measure of drug reinforcement were greater with AL than with DN. The dissociation between psychomotor-memory performance effects and various subjective effects demonstrates a novel pharmacological profile of DN.
UR - http://www.scopus.com/inward/record.url?scp=0028909782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028909782&partnerID=8YFLogxK
U2 - 10.1037/1064-1297.3.1.39
DO - 10.1037/1064-1297.3.1.39
M3 - Article
AN - SCOPUS:0028909782
SN - 1064-1297
VL - 3
SP - 39
EP - 48
JO - Experimental and clinical psychopharmacology
JF - Experimental and clinical psychopharmacology
IS - 1
ER -